中国药业2017，Vol.26Issue(15)：54-56,3.DOI:10.3969/j.issn.1006-4931.2017.15.018
多西他赛联合表柔比星治疗中晚期乳腺癌45例临床研究
Clinical Study of Docetaxel Combined with Epirubicin for Treating Moderate and Advanced Breast Cancer in 45 Cases
曹秀霞1
作者信息
- 1. 河南省商丘市第三人民医院肿瘤科,河南商丘 476000
- 折叠
摘要
Abstract
Objective To explore the therapeutic effect of docetaxel combined with epirubicin in the treatment of moderate and advanced breast cancer and its nursing measures. Methods Totally 90 patients with moderate and advanced breast cancer were randomly divided into two groups, 45 cases in each group. The control group was given cyclophosphamide, epirubicin combined with fluorouracil chemotherapy, while the observation group were treated with docetaxel combined with epirubicin chemotherapy, the two groups were given specific nursing. Results The total effective rate of the observation group was 75. 56%, which was higher than 53. 33% of the control group( P < 0. 05 ) . The Karnofsky score, survival time and nursing satisfaction in the observation group were better than those in the control group( P < 0. 05). The adverse reactions of bone marrow hematopoietic function, phlebitis, allergic reactions in the observation group were better than those in the control group ( P < 0. 05 ) . Conclusion Docetaxel combined with epirubicin in the treatment of moderateand advanced breast cancer has good effect, comprehensive and systematic nursing can alleviate the adverse reaction of chemotherapy, it can ensure the successful completion of chemotherapy, and effectively improve the clinical efficacy and quality of life of patients.关键词
多西他赛/表柔比星/乳腺癌/临床疗效/护理Key words
docetaxel/epirubicin/breast cancer/clinic efficacy/nursing care分类
医药卫生引用本文复制引用
曹秀霞..多西他赛联合表柔比星治疗中晚期乳腺癌45例临床研究[J].中国药业,2017,26(15):54-56,3.
